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Abstract. The use of tamoxifen for breast cancer therapy is 
linked to an increased danger of developing endometrial 
neoplasias in postmenopausal patients receiving the drug. 
Understanding the molecular mechanisms of the tumorigenic 
activity of tamoxifen may be of great prognostic and 
therapeutic significance. Our study suggests that tamoxifen 
treatment and alterations of the K-ras proto-oncogene may 
occur as parallel events in carcinogenesis of the endometrium. 
Introduction 
Tamoxifen, a non-steroidal compound, is widely used in 
therapy of estrogen-receptor rich breast carcinoma, because it 
acts as an agonist and down-regulates the stimulatory effect 
of the hormone-receptor complex. In addition, it alters the 
cellular metabolism of estradiol to less growth stimulating 
compounds (1). Use of the drug is proved to significantly 
reduce recurrence from early stages of the disease and the 
risk of a new primary cancer development (2). However, 
since postmenopausal patients are relatively hypoestrogenic, 
tamoxifen may stimulate endometrial growth. 
A number of cases of endometrial carcinoma associated 
with the use of tamoxifen have been reported (3,4). This 
effect is thought to be due to estrogenic stimulation of the 
uterine endometrium by the anti-estrogen, however, the 
molecular mechanisms of the neoplasia caused by tamoxifen 
are still unclear. Experimental results provide evidence for 
transcriptional activation of c-fos and c-jun-Ώ proto-
oncogenes by tamoxifen (5), which may result in alterations 
in AP-1 levels and in abnormal expression of a variety of 
AP-1 regulated genes, ras gene contains AP-1 responsive 
elements (6). Moreover, c-jun and/ral are crucial mediators 
of the ras-transformation process (7). 
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The Ras proteins play a central role in regulating cell 
growth and their mutations can lead to abnormal proliferation 
and carcinogenesis (8), usually in combination with 
additional oncogenic events, e.g viral infections (9). 
We report a case of endometrial adenocarcinoma in & 
breast cancer patient treated with tamoxifen. Using PCR-
RFLP analysis, we detected a mutation of the K-ras proto­
oncogene in the endometrial tumor tissue, thus suggesting 
that tamoxifen may exert its neoplastic effect in the uterus 
through mutational activation of cellular oncogenes. 
Case report 
An 81-year-old woman underwent a right radical mastectomy 
for an infiltrating carcinoma in 1978. Bone scintigraphy 
detected positive areas of metastases, as well. She was treated 
with tamoxifen as adjuvant therapy for 13 years (10 mg, three 
times daily). She had a diagnostic curettage for metrorrhagia 
in April 1991 and the histological report indicated an 
endometrial adenoacanthoma, Grade II, moderately 
differentiated. The patient underwent total abdominal 
hysterectomy with bilateral oophorectomy (FIGO Stage IB) 
and died a few weeks later. 
Materials and methods 
DNA extraction. Three 10 μπι thick sections from each 
formalin-fixed, paraffin-embedded tissue sample were de-
paraffinized by xylene, followed by an ethanol wash, lysed in 
a solution containing 10 mM Tris-HCl pH 8.0, 25 mM EDTA, 
100 mM NaCl, 0.5% SDS and 100 μg/ml proteinase K, and 
incubated at 60°C, for 24 h. The samples were then extracted 
with phenol, phenol/chloroform and chloroform and DNA 
was ethanol precipitated and resuspended in 30 μΐ of double 
distilled water. Samples were: endometrial tumor tissue from 
the breast cancer patient previously treated with tamoxifen 
and adjacent normal tissue from the same patient. 
Primers and PCR amplification. The oligonucleotide primers 
used for detection of K-ras codon 12 mutations have been 
previously described (10). 
One μΐ of the extracted DNA sample, or two μΐ of the 
control SW480 cell line encompassing K-ras codon 12 
mutation (10), were amplified in a reaction mixture of 50 μΐ, 
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containing 10 mM Tris-HCl pH 8.3, 50 raM KCl, 3.5 mM 
MgCl2, 200 μΜ of each dNTP, 1 μΜ of each primer and 2.5 U 
Taq polymerase (Perkin Elmer, Roche Molecular Systems, 
Inc., USA). The mixture was heated for 5 min at 98°C before 
addition of the polymerase, and then subjected to 35 cycles 
of amplification: denaturation at 94"C for 50 sec, annealing at 
58°C for 45 sec and elongation at 72"C for 50 sec, increasing 
the elongation time 1 sec per cycle. 
RFLP analysis. 20 μΐ aliquots of the amplification products 
were digested with 50 U of BstNI (New England Biolabs, 
UK), for 3 h, at 60"C. K-ras codon 12 positive samples give 
a 142 bp band after digestion, whereas negative samples 
produce a 113 bp band (10). 
Results and Discussion 
K-ras codon 12 point mutations are implicated in the 
development of primary endometrial carcinomas (10). Using 
PCR-RFLP analysis, we detected a K-ras codon 12 mutation 
in the endometrial tumor tissue of the breast cancer patient 
previously treated with tamoxifen, whereas no point mutation 
was detected in the adjacent normal tissue (Fig. 1). Lane 1 
represents undigested PCR product (157 bp) and lane 2 a 
positive control SW480 cell line, homozygous for K-ras 
codon 12 mutation (10). Lane 3 represents the adjacent 
normal endometrial tissue of the patient and the 113 bp band 
is clearly shown. The endometrial tumor tissue PCR-RFLP 
product is electrophoresed in lane 4. A light 142 bp band is 
shown, demonstrating that the sample is homozygous for 
K-ras codon 12 mutation. The 113 bp band in lane 4 is due to 
the normal tissue present in the sections (if the sample was 
heterozygous, the 142 bp and the 113 bp bands should have 
the same intensity). 
In a previous study, we reported that K-ras mutations are 
implicated in endometrial cancer of the Greek population in 
15% of cases (8/55) (10). Among the 55 patients tested, the 
case reported here was the only one previously treated with 
tamoxifen. Although only one patient with endometrial 
cancer who had received tamoxifen was examined, the low 
background rate (12.7%, 7/55) of K-ras point mutations 
detected in endometrial carcinomas of the Greek population, 
enables us to suggest a correlation between the use of 
tamoxifen and endometrial carcinogenesis. 
Tamoxifen is a drug with successful application in the 
treatment of primary breast cancer. However, it has estrogen 
agonist activity in the endometrium of postmenopausal 
women and creates an environment which stimulates cell 
division and growth of the target organ (11). Induction of 
proto-oncogene expression was reported as a mechanism of 
endometrial tumorigenesis associated with chronic tamoxifen 
treatment (5). We report mutational activation of K-ras 
proto-oncogene as an additional mechanism of tamoxifen-
induced carcinogenesis. Since tamoxifen induces elevated 
rates of cellular growth and division, we propose that 
endometrial cells have a predisposition to develop mutational 
alterations in cellular oncogenes, for example due to DNA 
polymerase errors or in addition to a second tumorigenic 
event, e.g. a mutagen, thus leading to an increased oncogenic 
potential. 
Figure 1. Detection of K-ras codon 12 point mutations by PCR-RFLP 
analysis. PCR products were digested with BstN I restriction endonuclease 
and electrophoresed through a 4% agarose gel. Lane 1, undigested PCR 
product, 157 bp; lane 2, positive control (SW480 cell line), 142 bp; lane 3, 
negative sample (normal tissue), 113 bp; lane 4, positive sample (tumor 
tissue), 142 bp. Lane M, molecular weight marker pUCI8/ Haelll. mt, 
mutation; wt, wild-type. 
Association between endometrial cancer and therapy with 
tamoxifen cannot be ignored (3). Vaginal and endometrial 
cytology, vaginal sonography and a strict gynecological 
follow-up were proposed to prevent this side effect of the 
drug (3). Combination of these methods with molecular 
techniques, for example detection of proto-oncogene 
mutations, may contribute to the earlier diagnosis of the 
disease and provide alternative methods of gene therapy. 
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